专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20110224129A1 Lipopeptide Compounds and Their Use 有权
标题翻译：脂肽化合物及其用途
公开(公告)号：US20110224129A1
公开(公告)日：2011-09-15
申请号：US13128661
申请日：2009-11-24
申请人： Rustum S. Boyce , Joseph Cherian , Cleofe Calanasan , Muhammad Sofian Asi Sihombing
发明人： Rustum S. Boyce , Joseph Cherian , Cleofe Calanasan , Muhammad Sofian Asi Sihombing
IPC分类号： A61K38/12 , C07K7/60 , A61P31/04
CPC分类号： C07K7/56 , A61K38/00
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain lipopeptide compounds comprising a cyclic peptide bearing a lipid side chain (for convenience, collectively referred to herein as “LP compounds”), which, inter alia, are antimicrobial, particularly antibacterial. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to provide an antimicrobial function, particularly an antibacterial function, and in the treatment of diseases and conditions that are mediated by microbes, particularly bacteria, that are ameliorated by the antimicrobial function, particularly an antibacterial function, including bacterial diseases, optionally in combination with another agent, for example, another antibacterial agent.
摘要翻译：本发明一般涉及治疗化合物领域，更具体地涉及包含带有脂质侧链的环状肽（为方便起见，统称为“LP化合物”）的某些脂肽化合物，其特别是抗微生物剂，特别是抗菌。本发明还涉及包含这种化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以提供抗微生物功能，特别是抗菌功能，以及用于治疗介导的疾病和病症特别是通过抗微生物功能改善的微生物，特别是细菌，特别是抗菌功能，包括细菌疾病，任选地与另一种试剂，例如另一种抗菌剂组合。

2. 发明申请

US20170326151A1 Compositions Comprising Finafloxacin And Tris 审中-公开
公开(公告)号：US20170326151A1
公开(公告)日：2017-11-16
申请号：US15523680
申请日：2015-10-09
申请人： MerLion Pharmaceuticals Pte. Ltd.
发明人： Carsten Fischer , Andreas Vente , Sven-Eric Wohlert
IPC分类号： A61K31/5383 , A61K9/00 , A61K47/02 , A61K47/18
CPC分类号： A61K31/5383 , A61K9/0019 , A61K9/08 , A61K47/02 , A61K47/18
摘要： It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.

3. 发明申请

US20110237566A1 Therapeutic Macrolide Compounds and Their Use 审中-公开
标题翻译：治疗性大环内酯类化合物及其用途
公开(公告)号：US20110237566A1
公开(公告)日：2011-09-29
申请号：US13130144
申请日：2009-11-24
申请人： Rustum S. Boyce , Muhammad Sofian Asi Sihombing , Hiroki Sone
发明人： Rustum S. Boyce , Muhammad Sofian Asi Sihombing , Hiroki Sone
IPC分类号： A61K31/553 , C07D313/00 , C07D413/14 , C07D405/14 , C07D267/10 , C07D243/08 , A61K31/336 , A61K31/5355 , A61K31/497 , A61K31/4523 , A61K31/551 , A61P35/00
CPC分类号： C07D407/06 , C07D403/14 , C07D405/14 , C07D413/14
摘要： The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain macrolide compounds (for convenience, collectively referred to herein as “MC compounds”), which, inter alia, are useful in treatment of cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to treat proliferative conditions such as cancer, and in the treatment of diseases and conditions that are mediated by the regulation (e.g. inhibition) of cell proliferation, optionally in combination with another agent.
摘要翻译：本发明一般涉及治疗化合物的领域，更具体地涉及某些大环内酯类化合物（为方便起见，本文统称为“MC化合物”），其尤其可用于治疗癌症。本发明还涉及包含这些化合物的药物组合物，以及这些化合物和组合物在体外和体内的用途，以治疗增殖性疾病如癌症，以及治疗由调节介导的疾病和病症（例如抑制）细胞增殖，任选与另一种试剂组合。

4. 发明授权

US10485805B2 Finafloxacin for use in the treatment of urinary tract infections 有权
公开(公告)号：US10485805B2
公开(公告)日：2019-11-26
申请号：US15541543
申请日：2015-11-10
申请人： MerLion Pharmaceuticals Pte. Ltd.
发明人： Christine Bentley , Carsten Fischer , Mark Lückermann , Andreas Vente , Sven-Eric Wohlert
IPC分类号： A61K31/5383
CPC分类号： A61K31/5383
摘要： It was found that finafloxacin eradicates pathogens from patients suffering from bacterial infections like urinary tract infections and pyelonephritis more quickly than other fluoroquinolones regularly used for the treatment of these patients. Due to the efficacy of finafloxacin reduced treatment durations without increasing the daily dosage of finafloxacin and at the same time no or shorter stays in hospital are realizable, thus improving patient convenience and significantly lowering the costs of hospitalization and treatment. Reduced hospitalization periods do also clearly reduce the risk of nosocomial infections and of generating drug-resistant strains through extended therapy. The inventive treatment regimens comprise an oral finafloxacin administration for 1-5 days or a parenteral finafloxacin administration for 1-5 days for use in the treatment of a complicated urinary tract infection or pyelonephritis. However, a prior short parenteral administration of finafloxacin (e.g. 3 days) in combination with an oral administration (e.g. 2 days) may be applied, if necessary in case of really severe infections. The present invention further relates to a novel treatment regime for the treatment of uncomplicated UTI whereby a single oral finafloxacin dose is considered to be sufficient to effectively treat patients with uncomplicated UTI.

5. 发明授权

US10576088B2 Compositions comprising finafloxacin and Tris 有权
公开(公告)号：US10576088B2
公开(公告)日：2020-03-03
申请号：US15523680
申请日：2015-10-09
申请人： MerLion Pharmaceuticals Pte. Ltd.
发明人： Carsten Fischer , Andreas Vente , Sven-Eric Wohlert
IPC分类号： A61K31/5383 , A61K9/00 , A61K47/02 , A61K47/18 , A61K9/08
摘要： It was found that finafloxacin has a high solubility in the presence of Tris. Such solubility is significantly higher than in the presence of other compounds typically used as buffers (e.g. phosphate buffer). The observed significant increase in solubility of finafloxacin in compositions comprising Tris is further advantageously accompanied by a long term stability of such solutions. Tris is therefore to be regarded as a specific tool to considerably enhance the solubility of finafloxacin in solutions. By preparing compositions comprising Tris it is possible to dissolve finafloxacin in such an amount therein that these compositions can effectively be used as parenteral compositions for the treatment of bacterial infections.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式